Nolwenn Juhel
- Efficacy of BIBF 1120 in patients with IPF is dose-dependent: Results from the TOMORROW trialBy Ulrich Costabel, Luca Richeldi, Moises Selman, Dong Soon Kim, Kevin K. Brown, Kevin R. Flaherty, Paul W. Noble, Ganesh Raghu, Michèle Brun, Abhya Gupta, Matthias Klueglich, Nolwenn Juhel and Roland M. du BoisUlrich Costabel1Ruhrlandklinik and Medical Faculty, University of Duisburg-Essen, Essen, GermanyLuca Richeldi2Center for Rare Lung Disease, University of Modena and Reggio Emilia, Modena, ItalyMoises Selman3Instituto Nacional de Enfermedades Respiratorias, “Ismael Cosio Villegas”, México, MexicoDong Soon Kim4Division of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, KoreaKevin K. Brown5Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, National Jewish Health, Denver, United StatesKevin R. Flaherty6Department of Internal Medicine, Pulmonary and Critical Care Division, University of Michigan, Ann Arbor, United StatesPaul W. Noble7Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, United StatesGanesh Raghu8Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, United StatesMichèle Brun9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceAbhya Gupta10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyMatthias Klueglich10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyNolwenn Juhel9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceRoland M. du Bois11National Heart & Lung Institute, Imperial College, London, United Kingdom
- Effect of baseline FVC on preservation of lung function with BIBF 1120: Results from the TOMORROW trialBy Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, Kevin R. Flaherty, Paul W. Noble, Ganesh Raghu, Arata Azuma, Michèle Brun, Abhya Gupta, Matthias Klueglich, Nolwenn Juhel and Roland M. du BoisLuca Richeldi1Center for Rare Luna Disease, University of Modena and Reggio Emilia, Modena, ItalyUlrich Costabel2Ruhrlandklinik and Medical Faculty, University of Duisburg-Essen, Essen, GermanyMoises Selman3Instituto Nacional de Enfermedades Respiratorias, “Ismael Cosio Villegas”, Mèxico, MexicoDong Soon Kim4Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan, Seoul, KoreaKevin R. Flaherty5Department of Internal Medicine, Pulmonary and Critical Care Division, University of Michigan, Ann Arbor, United StatesPaul W. Noble6Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, United StatesGanesh Raghu7Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, United StatesArata Azuma8Division of Respiratory Medicine, Infection and Oncology, Nippon Medical School, Tokyo, JapanMichèle Brun9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceAbhya Gupta10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyMatthias Klueglich10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyNolwenn Juhel9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceRoland M. du Bois11National Heart & Lung Institute, Imperial College, London, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.